Dr. Rosenthal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5777 E. Mayo Boulevard
Phoenix, AZ 85050
Summary
- Dr. Allison Rosenthal is a hematologist in Phoenix, AZ and is affiliated with Mayo Clinic Hospital. She received her medical degree from Arizona College of Osteopathic Medicine of Midwestern University and has been in practice 8 years. She specializes in hematologic oncology and is experienced in cutaneous lymphomas, non-hodgkin lymphoma, thrombocytopenia, hodgkin's lymphoma, and lymphoma. She has more than 80 publications and over 500 citings.
Education & Training
Mayo Clinic College of Medicine and Science (Phoenix)Fellowship, Hematology and Medical Oncology, 2012 - 2015
Creighton University School of Medicine (Phoenix)Residency, Internal Medicine, 2009 - 2012
Arizona College of Osteopathic Medicine of Midwestern UniversityClass of 2009
Certifications & Licensure
AZ State License 2012 - 2025
MN State License 2015 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL Start of enrollment: 2020 Sep 07
- Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Start of enrollment: 2021 Apr 01
- DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Roles: Contact
Publications & Presentations
PubMed
- 8 citationsNext-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma.Jacob D Soumerai, Allison Rosenthal, Shannon Harkins, Jessica Duffy, Carmen Mecca
Blood. 2022-10-20 - 4 citationsEfficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.Madiha Iqbal, Deepa Jagadeesh, Julio Chavez, Arushi Khurana, Allison Rosenthal
Bone Marrow Transplantation. 2024-02-01 - 5 citationsIncorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.Omran Saifi, Scott C Lester, William G Breen, William G Rule, Yi Lin
American Journal of Hematology. 2024-01-01
Press Mentions
All-Star Pitcher Liam Hendriks Shares How He Closed Out Cancer at Mayo Clinic in ArizonaJuly 27th, 2023- Charting the Course: From Young Adult Leukemia Patient to OncologistDecember 5th, 2023
- Meeting the Needs of Young People with CancerApril 3rd, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
